Aureus Asset Management LLC Buys 12,324 Shares of Bristol-Myers Squibb Company (BMY)
Aureus Asset Management LLC grew its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 6.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 200,230 shares of the biopharmaceutical company’s stock after purchasing an additional 12,324 shares during the period. Bristol-Myers Squibb comprises approximately 1.9% of Aureus Asset Management LLC’s investment portfolio, making the stock its 27th largest holding. Aureus Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $11,157,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. Connecticut Wealth Management LLC purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at approximately $224,000. Birmingham Capital Management Co. Inc. AL lifted its position in shares of Bristol-Myers Squibb by 4.4% during the 1st quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after buying an additional 3,000 shares in the last quarter. HGK Asset Management Inc. lifted its position in shares of Bristol-Myers Squibb by 20.8% during the 1st quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after buying an additional 53,221 shares in the last quarter. Investment Partners Ltd. OH ADV lifted its position in shares of Bristol-Myers Squibb by 1.4% during the 1st quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock valued at $1,107,000 after buying an additional 274 shares in the last quarter. Finally, Goelzer Investment Management Inc. lifted its position in shares of Bristol-Myers Squibb by 85.4% during the 1st quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock valued at $4,100,000 after buying an additional 34,735 shares in the last quarter. Institutional investors and hedge funds own 69.82% of the company’s stock.
In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is owned by company insiders.
BMY has been the topic of a number of recent analyst reports. Credit Suisse Group reiterated a “hold” rating and set a $61.00 target price (up previously from $58.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Cowen reiterated a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, September 19th. Jefferies Group increased their target price on Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, September 11th. Piper Jaffray Companies reiterated a “hold” rating and set a $60.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 27th. Finally, Leerink Swann increased their target price on Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. One analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $64.93.
Bristol-Myers Squibb Company (NYSE BMY) opened at $62.42 on Friday. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $102,146.61, a price-to-earnings ratio of 21.08, a P/E/G ratio of 2.37 and a beta of 1.18.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the company posted $0.77 earnings per share. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.
TRADEMARK VIOLATION WARNING: “Aureus Asset Management LLC Buys 12,324 Shares of Bristol-Myers Squibb Company (BMY)” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.watchlistnews.com/aureus-asset-management-llc-buys-12324-shares-of-bristol-myers-squibb-company-bmy/1755332.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.